Inflammatory bowel disease (IBD) is a chronic, immunologically mediated disorder of the gastrointestinal tract in which tissue damage and sustained inflammation lead to long-term dysfunction of the gastrointestinal tract.
An experimental antibiotic was able to prevent recurrent Clostridioides difficile infections (rCDI) by killing bacterial spores as well as growing spores. Researchers from the University of Notre Dame reported their findings in the Proceedings of the National Academy of Sciences on May 8, 2023.
Researchers based at Uppsala University in Sweden have created an adeno-associated viral (AAV) vector treatment for glioma or glioblastoma that extended survival in a mouse model of the brain cancer. Writing in the May 11, 2023, issue of Cancer Cell, the researchers reported that by introducing an inflammatory protein known as LIGHT to the tumor microenvironment using the AAV treatment, the mice were better able to fight the cancer.
Nicoya Therapeutics (Shanghai) Co. Ltd. has reported the identification of compounds acting as dual endothelin ETA receptor and angiotensin AT1 receptor antagonists.
S-Adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors have been described in an Insilico Medicine IP Ltd. patent as potentially useful for the treatment of cancer.
Immunophage Biomedical Co. Ltd. have prepared and tested G-protein coupled receptor 183 (GPR183; EBI2) antagonists that are reported to be useful for the treatment of autoimmune disease, cancer, liver diseases, osteoporosis and neuropathic pain.
RSS
